Sponsored by
Very interesting. They found that MAPK mutations in diffuse midline glioma actually leads to longer survival. MAPK mutations have been hard to target but there is a new drug in clinical trials called Ulixertinib. The are a few clinical trials for this drug and there is also a expanded access program (run by my team at xCures) for those who do not fit into the trials. May be worth considering if you have one of these mutations: including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations